Format

Send to:

Choose Destination
See comment in PubMed Commons below
Toxicol Pathol. 2014 Jun;42(4):672-83. doi: 10.1177/0192623313518664. Epub 2014 Feb 4.

Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury.

Author information

  • 1Global Safety Assessment, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA David.Brott@astrazeneca.com.
  • 2Global Safety Assessment, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.
  • 3Safety Assessment, Pathology, GlaxoSmithKline, King of Prussia, Pennsylvania, USA.
  • 4Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut, USA.
  • 5BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA.
  • 6Department of Environmental Health Sciences, The University of Michigan, Ann Arbor, Michigan, USA.
  • 7Drug Safety Sciences, Janssen Pharmaceuticals, Spring House, Pennsylvania, USA.

Abstract

Pharmacologically, vasoactive agents targeting endothelial and/or smooth muscle cells (SMC) are known to cause acute drug-induced vascular injury (DIVI) and the resulting pathology is due to endothelial cell (EC) perturbation, activation, and/or injury. Alteration in EC structure and/or function may be a critical event in vascular injury and, therefore, evaluation of the circulatory kinetic profile and secretory pattern of EC-specific proteins such as VWF and VWFpp could serve as acute vascular injury biomarkers. In rat and dog models of DIVI, this profile was determined using pharmacologically diverse agents associated with functional stimulation/perturbation (DDAVP), pathological activation (lipopolysaccharide [LPS]/endotoxin), and structural damage (fenoldopam [FD], dopamine [DA], and potassium channel opener (PCO) ZD6169). In rats, FD caused moderate DIVI and time-related increase in plasma VWF levels ∼33% while in control rats VWF increased ∼5%. In dogs, VWF levels transiently increased ∼30% when there was morphologic evidence of DIVI by DA or ZD6169. However, in dogs, VWFpp increased >60-fold (LPS) and >6-fold (DDAVP), respectively. This was in comparison to smaller dynamic 1.38-fold (LPS) and 0.54-fold (DDAVP) increases seen in plasma VWF. Furthermore, DA was associated with a dose-dependent increase in plasma VWFpp. In summary, VWF and VWFpp can discriminate between physiological and pathological perturbation, activation, and injury to ECs.

© 2014 by The Author(s).

KEYWORDS:

DDAVP.; DIVI; LPS; VWF; VWFpp; activation; biomarker; dog; endothelial cell; perturbation; rat

PMID:
24499802
[PubMed - indexed for MEDLINE]
PMCID:
PMC4222990
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk